Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2012 Feb 15;69(6):1657–1667. doi: 10.1007/s00280-012-1839-5

Table 3.

Grade 3 & 4 hematologic and non-hematologic toxicities possibly, probably, or definitely related to study treatment occurring during any treatment course

Hematologic Toxicities Stratum 1*
no. of patients
(%)		 Stratum 2*
no. of patients
(%)
Anemia 0 (%) 3 (50%)
Leukopenia 0 (0%) 2 (33%)
Lymphopenia 0 (0%) 1 (17%)
Neutropenia 4 (27%) 2 (33%)
Thrombocytopenia 1 (7%) 3 (50%)
Non-Hematologic Toxicities Stratum 1*
no. of patients
(% patients)		 Stratum 2*
no. of patients
(% patients)
Cholecystitis 1 (7%) 0 (0%)
Diarrhea 1 (7%) 0 (0%)
Febrile Neutropenia 0 (0%) 1 (17%)
Hypophosphatemia 1 (7%) 0 (0%)
Infection-NOS 1 (7%) 0 (0%)
Infection with normal ANC: upper respiratory-NOS 0 (0%) 1 (17%)
Multi-organ failure (grade 5) 0 (0%) 1 (17%)
*

Patients with <15% blasts in PB and BM, and no recent myelosuppressive therapy were assigned to stratum 1. Patients with ≥15% blasts in the BM or PB were assigned to stratum 2, as were patients with <15% blasts who had grade 1 or 2 neutropenia or thrombocytopenia from previous myelosuppressive therapy.